Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,402,551
  • Shares Outstanding, K 100,582
  • Annual Sales, $ 2,861 M
  • Annual Income, $ 478,600 K
  • EBIT $ 619 M
  • EBITDA $ 637 M
  • 60-Month Beta 0.35
  • Price/Sales 4.52
  • Price/Cash Flow 25.62
  • Price/Book 3.94

Options Overview Details

View History
  • Implied Volatility 48.01% (+3.81%)
  • Historical Volatility 26.17%
  • IV Percentile 94%
  • IV Rank 62.75%
  • IV High 63.24% on 04/21/25
  • IV Low 22.35% on 08/29/25
  • Expected Move (DTE 25) 12.07 (9.17%)
  • Put/Call Vol Ratio 0.30
  • Today's Volume 43
  • Volume Avg (30-Day) 223
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 11,499
  • Open Int (30-Day) 9,480
  • Expected Range 119.52 to 143.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.27
  • Number of Estimates 4
  • High Estimate $1.78
  • Low Estimate $1.01
  • Prior Year $0.08
  • Growth Rate Est. (year over year) +1,487.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
125.11 +5.18%
on 03/24/26
134.20 -1.94%
on 04/07/26
+3.91 (+3.06%)
since 03/20/26
3-Month
122.14 +7.74%
on 02/12/26
142.82 -7.86%
on 02/10/26
-2.95 (-2.19%)
since 01/20/26
52-Week
98.95 +32.99%
on 04/21/25
160.18 -17.85%
on 12/08/25
+30.21 (+29.80%)
since 04/17/25

Most Recent Stories

More News
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR

SAN DIEGO , April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced the presentation of new real-world evidence demonstrating that adult patients with tardive...

NBIX : 131.59 (-1.25%)
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

VYKAT™  XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in  Prader-Willi Syndrome and Represents a Transformative Therapy

NBIX : 131.59 (-1.25%)
SLNO : 52.67 (-0.21%)
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings

SAN DIEGO , March 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced the presentation of the first expert consensus recommendations focused on screening,...

NBIX : 131.59 (-1.25%)
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer

SAN DIEGO , March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical...

NBIX : 131.59 (-1.25%)
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum

SAN DIEGO , March 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the Stifel 2026 Virtual CNS Forum at...

NBIX : 131.59 (-1.25%)
BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)

TROY, Mich. , March 6, 2026 /PRNewswire/ -- Equifax Inc.'s recent report has investors wondering if the company's stock is fairly valued. Or is it in the buy range? As such, the Editorial Advisory...

EFX : 198.45 (+1.14%)
NBIX : 131.59 (-1.25%)
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

SAN DIEGO , Feb. 24, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:

NBIX : 131.59 (-1.25%)
Neurocrine: Q4 Earnings Snapshot

Neurocrine: Q4 Earnings Snapshot

NBIX : 131.59 (-1.25%)
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026

Total Fourth-Quarter and Full-Year 2025 Net Product Sales of $798.3 Million and $2.83 Billion , Representing Year-Over-Year Growth of 29% and 22%, Respectively

NBIX : 131.59 (-1.25%)
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia

SAN DIEGO , Jan. 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults...

NBIX : 131.59 (-1.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 137.47
2nd Resistance Point 135.79
1st Resistance Point 133.69
Last Price 131.59
1st Support Level 129.91
2nd Support Level 128.23
3rd Support Level 126.13

See More

52-Week High 160.18
Fibonacci 61.8% 136.79
Last Price 131.59
Fibonacci 50% 129.56
Fibonacci 38.2% 122.34
52-Week Low 98.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.